Table 1.
In vitro support for lipid interactions with OAT1
| Metabolite | Ki (μM) | IC50 (μM) | Inhibition | Reference |
|---|---|---|---|---|
| Bile Acids | ||||
| Taurocholate | 2800 | (10) | ||
| Short-Chain Fatty Acids | ||||
| 3-Hydroxybutyrate | 3220 | (54) | ||
| β-Hydroxybutyrate | 1023 | (25) | ||
| Butyrate | 3500 | (55) | ||
| Propionate | 8083 | (54) | ||
| Prostaglandins | ||||
| Prostaglandin E1 | 12 | (24) | ||
| Prostaglandin E2 | 3.4 | (55) | ||
| Prostaglandin F2α | 0.57 | (56) | ||
| Long-Chain Fatty Acids | ||||
| 16-Hydroxy-hexadecanoic acid | 13 | (10) | ||
| Hexadecanedioate | 30–70% Inhibition | (57) | ||
| Palmitoleic acid | 200 | (24) | ||
| Pentadecanoic acid | 102.9 | This study | ||
| Tetradecanedioate | 30–70% Inhibition | (57) | ||
| Medium-Chain Fatty Acids | ||||
| Adipic acid | 0.41 | (55) | ||
| Heptanoate | 16.7 | (55) | ||
| Hexanoate | 38 | (55) | ||
| Octanoate | 5.41 | (58) | ||
| Suberate | 34.19 | (55) | ||
| Dicarboxylic Acids | ||||
| Fumarate | 610 | (55) | ||
| Glutarate | 6.7 | (55) | ||